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Neuropilin-2 is a transmembrane receptor involved in lymphangiogenesis
and neuronal development. In adults, neuropilin-2 and its homologous pro-
tein neuropilin-1 have been implicated in cancers and infection. Molecular
determinants of the ligand selectivity of neuropilins are poorly understood.
We have identified and structurally characterized a zinc ion binding site on
human neuropilin-2. The neuropilin-2-specific zinc ion binding site is
located near the interface between domains b1 and b2 in the ectopic region
of the protein, remote from the neuropilin binding site for its physiological
ligand, i.e. vascular endothelial growth factor. We also present an X-ray
crystal structure of the neuropilin-2 b1 domain in a complex with the
C-terminal sub-domain of VEGF-A. Zn2+ binding to neuropilin-2 destabi-
lizes the protein structure but this effect was counteracted by heparin, sug-
gesting that modifications by glycans and zinc in the extracellular matrix
may affect functional neuropilin-2 ligand binding and signalling activity.
Introduction
Neuropilin-2 (NRP2) and neuropilin-1 (NRP1) are
homologous transmembrane receptors that are
expressed in diverse tissues, sharing a common domain
organization and 44% amino acid sequence identity in
humans [1–3]. Both NRPs have essential roles in the
control of axonal homing in the developing nervous
system, as revealed by the phenotypes of genetically
deficient mice [4–7]. NRP1 is also required for embry-
onic cardiovascular development, whereas NRP2 has a
more restricted developmental role in lymphangiogene-
sis [7]. In addition, neuropilins have been implicated in
other physiological and disease-related processes in
adult organisms, such as various cancers, proliferative
retinopathies and immunomodulation [8].
Neuropilins mediate signalling by binding to vascu-
lar endothelial growth factors (VEGFs) and semaphor-
ins, secreted ligands that are essential for
cardiovascular and neuronal development, respectively
[9–14]. The ligand specificities for NRPs are often
found overlap in cell-based studies, whereas NRP1
and NRP2 display distinct expression patterns and
ligand preferences in vivo [6,11,15,16]. In the central
nervous system, for example, the semaphorin Sema3A
preferentially signals via NRP1 to control cortical
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neuron basal dendritic arborization, whereas Sema3F
binds NRP2 to regulate formation of apical dendrite
processes of cortical neurons [17]. In the vascular sys-
tem, the ligand preferences for NRPs are less clearly
defined, but the VEGF-A splice variant VEGF-A165
appears to be a major ligand for NRP1 on endothelial
cells, whereas VEGF-C signals via NRP2 in lymphatic
vessels [9,11,18–20]. Furthermore, NRP2 is co-
expressed with NRP1 in endothelial and other cell
types, NRP2 and NRP1 may associate to form hetero-
dimers [14], and NRP2 also binds to VEGF-A in tri-
meric complexes with VEGF receptor 2 [21,22],
suggesting that NRPs have the potential to interact in
a cooperative fashion in the endothelium.
The protein regions of VEGF-A encoded by exons
2-5 form a cysteine knot structure that interacts with
VEGF receptors, while the 55 amino acid residue
C-terminal domain of VEGF-A, encoded by exons 7
and 8, is required for binding to neuropilin and hep-
arin [23,24]. Several structural and biochemical studies
have addressed the molecular basis of the VEGF bind-
ing selectivity of neuropilins. In all of the available
structures, including those of a small molecule pep-
tidomimetic in complex with NRP1 and of a fusion of
the NRP1 binding region of VEGF-A with the NRP1
b1 domain, a key feature is binding of a C-terminal
arginine residue to a conserved region of the b1
domain of neuropilin [25–27]. Crystal structures of a
fusion of human NRP1 b1 (NRP1 residues 274–429)
with the heparin binding domain (HBD) of VEGF-
A165 (VEGF-A165-HBD; VEGF-A165 residues 115–165)
[26] or of human NRP2 domains b1b2 (NRP2 residues
276–595) fused with the C-terminal five amino acids of
mature VEGF-C (SIIRR, residues 219–223) [27]
revealed a high degree of similarity with respect to the
interactions of the C-terminal arginine residue of
VEGF-A165 and VEGF-C with NRP1 and NRP2,
respectively. Initial site-directed mutagenesis experi-
ments addressing sequence differences in the binding
sites of NRP1 and NRP2 have led to the proposal that
a charge repulsion mechanism provides the molecular
basis for ligand selectivity [26,27]. However, more
comprehensive structural and functional studies of
NRP2, including other members of the VEGF ligand
family, are needed to fully characterize and understand
the molecular basis for both VEGF binding to NRP2
and differences between NRP1 and NRP2 in terms of
ligand preference and biological function.
We now report structural and biochemical charac-
terization of a conserved Zn2+ ion binding site on
NRP2. This binding site is not present in NRP1, and
we hypothesize that it may be involved in modulation
of ligand binding to NRP2. In addition, we describe
the three-dimensional structure of a molecular complex
between the C-terminal region of VEGF-A165 and the
b1 ligand binding domain of NRP2, further addressing
the question of ligand selectivity.
Results
Crystal structure reveals a NRP2-specific zinc ion
binding site
We have solved a structure of NRP2 from the crystal
grown in the presence of zinc sulfate that diffracted to
1.8 A resolution (Fig. 1 and Table 1). No specific pep-
tidic ligand was present during the crystallization, but
the ligand binding pocket showed a difference electron
Fig. 1. Zn2+ binding site on NRP2. (A) The
X-ray crystal structure of NRP2 crystallized
in the presence of zinc revealed three zinc
ions bound to the b1 domain. The
structure is shown in yellow ribbon
representation, and the three zinc ions are
shown as grey spheres. A molecule of
MES (2-ethanesulfonic acid) bound to the
canonical ligand binding site on the
neuropilin b1 domain is shown using
sticks representation. Loops L1 and L3
that shape the binding cleft are indicated.
(B) Enlarged view of the ligand binding
site, with the MES-associated 2 Fo – Fc
electron density map shown as a grey
wire mesh and contoured at 1 r.
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density that was consistent with a molecule of MES
buffer (2-ethanesulfonic acid) present in the mother
liquor, although with the significant disorder of the
morpholine ring (Fig. 1). In addition, three zinc ion
binding sites were identified in the difference electron
density maps, and the location of zinc ions was veri-
fied by an anomalous difference map (Fig. 1A). The
most significant zinc ion binding site (referred to as
site ‘1’) is formed by the side chains of the amino acids
Tyr375, His377 and His399, with the fourth zinc ion
coordination most likely provided by a chloride ion
from the protein buffer solution used for crystalliza-
tion (Fig. 2A). We interpreted the density as represent-
ing a chloride ion, as when water molecule was
modelled in that position, there was always strong
residual electron density left. The other two zinc ions
bound to NRP2 in this crystal structure are less likely
to be biologically relevant, and their binding sites have
probably been generated by the crystallization condi-
tions and crystal packing. Both of the additional two
binding sites are formed within the inter-molecular
space, with two zinc-coordinating side chains provided
by one molecule and the third side chain provided by
an amino acid of the crystallographic neighbour.
Specifically, the second zinc ion is coordinated by
Glu284 and His312 from one molecule and His415
from the neighbouring molecule; the third zinc ion is
coordinated by Lys362 and His381 from one molecule
and Glu370 from the neighbouring molecule. The zinc-
coordinating residues at site 1 of NRP2 are conserved
throughout mammalian species and unique to NRP2
as they are absent in NRP1 sequences (Fig. 2B), fur-
ther suggesting a specific physiological role for this
metal binding site. The orientation of the three coordi-
nating side chains in the presence of zinc ion within
our structure is different from that of the side chains
of equivalent residues in the previously reported NRP2
structure [28], reflecting adjustment of the side chain
conformations in order to accommodate ion binding.
Structure of a protein complex of the VEGF-A165
C-terminus and the NRP2 b1 domain
We also obtained a crystal structure of a protein com-
plex of peptide EG00086 (Fig. 3A) bound to the b1
domain of NRP2. Peptide EG00086, corresponding to
the C-terminus of VEGF-A165 (residues 138–165), its
binding affinity to NRP1 and NRP2, and its potency
to act as inhibitor of VEGF-promoted cellular adhe-
sion have been previously described [29]. The peptide
corresponds to the C-terminal half (one sub-domain) of
the HBD of VEGF-A165. The small sub-domain com-
prises short two-stranded anti-parallel b-sheet stabilized
by two disulfide bridges. The crystal structure of the
complex between the NRP2 b1 domain and EG00086
was refined to 1.95 A resolution, with four copies of
EG00086-bound NRP2 b1 in the asymmetric unit
(Fig. 3 and Table 1). In this structure, the C-terminal
arginine residue of the ligand EG00086 resides in the
conserved binding pocket of the NRP2 b1 domain
(Fig. 3C). The C-terminal carboxylate forms hydrogen
bonds with Ser349 and Thr352, while the Arg guani-
dinium group engages in ionic interaction with Asp323
at the base of the binding pocket. The aliphatic portion
of the Arg side chain is nestled between Tyr356 and
Tyr299, while the hydroxyl group of Tyr299 addition-
ally interacts with EG00086 through a hydrogen bond
with the backbone carbonyl oxygen of Pro163 of
EG00086 (or residue 230 in a canonical full-length
VEGF-A sequence, P15692-1) (Fig. 3C). The NRP2
side chains contributing to tethering of the C-terminal
arginine are conserved in the NRP1 binding pocket
[25,26,30], and have also been identified as being
involved in binding of VEGF-C within the structure of
an NRP2 fusion protein in which the C-terminus of the
NRP2 b1b2 protein product is fused to the last five
residues of proteolytically processed VEGF-C [27]. In
our structure of the complex between NRP2 b1
Table 1. Data collection and refinement statistics. Values in
parentheses are for the highest-resolution shell.
Crystal EG00086-bound Zn2+-bound
Data collection
X-ray source Diamond I03 ESRF ID23-2
Space group C2221 C2221
Cell constants
a, b, c (A) 110.25, 139.52,
106.04
99.39, 105.27,
45.75
a, b, c (°) 90.00, 90.00, 90.00 90.00, 90.00, 90.00
Resolution (A) 67.03–1.95
(2.00–1.95)
36.13–1.80
(1.84–1.80)
Completeness (%) 99.5 (97.4) 99.9 (99.8)
Multiplicity 3.4 (3.0) 4.6 (4.5)
Rmerge 0.059 (0.223) 0.052 (0.230)
<I/r(I)> 10.8 (4.3) 16.5 (5.4)
CC½ 0.996 (0.944) 0.997 (0.937)
Wilson B factor (A2) 23.3 21.7
Refinement
Number of reflections 59 661 22 736
Rwork/Rfree 0.204/0.234 0.177/0.217
Mean B value,
all atoms (A2)
26.0 25.5
RMSDs
Bond lengths (A) 0.010 0.016
Bond angles (°) 1.463 1.753
Ramachandran plot (%)
Favoured, allowed, 96, 4, 0 (chain A)
outliers 95, 5, 0 (chain B) 96, 4, 0
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domain and the EG00086 peptide, even though there
is sufficient space within the crystal packing to accom-
modate the entire EG00086 molecule, a significant por-
tion of the peptide appeared disordered, and, within
the tetrameric structure, only up to eight amino acids
of EG00086 per NRP2 binding site were modelled,
with some of the side chains not visible in the electron
density maps (Fig. 3C). While the C-terminus of the
peptide is well-tethered to the neuropilin molecule, the
rest of the structure displays multiple confirmations,
giving rise to crystallographic disorder. Even though
the peptide contains disulfide bonds, we were unable
to model with confidence the adjacent b-strand of the
b-hairpin structure. The structure of the complex
implies that the main function of the HBD of VEGF
may be to provide a specific but flexible connection
between the two partner receptors: neuropilin and the
VEGF receptor.
Intriguingly, in the EG00086-bound NRP2 structure
reported here and in the recently reported structure of
the protein fusion between the NRP2 b1b2 segment
and the C-terminal pentapeptide of proteolytically pro-
cessed VEGF-C [27], both VEGF-A165 and VEGF-C
bind to the same NRP2 binding site, and the same set
of hydrogen bonds and ionic interactions are involved
in binding of the C-terminal ligand residues. However,
we observe differences in the direction of the C-term-
inal VEGF-A165-related peptide between the structure
reported here and that reported for the structure of
the NRP1 b1–VEGF-A165-HBD fusion protein [26].
However, in both structures, effects of crystal packing
on positioning of the VEGF-A165 components of the
complexes could not be completely excluded. Our pre-
vious isothermal titration calorimetry (ITC) measure-
ments of the in vitro interaction between NRP1, NRP2
and EG00086 [29], and the crystal structures of the rel-
evant complexes, do not clarify the molecular basis for
the differences in biological activity. Considering that
qualitatively the same set of key molecular interactions
have been identified in all instances, it is possible that
additional factors such as the energy of the additional
hydrogen bonds within the NRP1/ligand and NRP2/
Fig. 2. The main zinc ion binding site is NRP2-specific. (A) Stereoimage of the NRP2 residues involved in Zn2+ ion coordination: Y375, H377
and H399. The residues are shown using stick representation within the final 2 Fo – Fc electron density map contoured at 1 r (grey mesh).
(B) Sequence alignment for the part of the neuropilin sequences that includes all three residues that bind zinc in site ‘1’ shows that the site
is conserved in NRP2 and absent in NRP1. The residues associated with NRP2 are highlighted in yellow, and the residues in the analogous
positions in NRP1 are highlighted in green.
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ligand complexes, entropic changes due to side chains
or solvent rearrangement within the ligand binding
sites, or structural differences and post-translational
modifications elsewhere on the proteins contribute to
the perceived differences in the ligand affinities of
NRP1 versus NRP2.
The zinc binding site in the NRP2 b1 domain is
remote from the VEGF ligand binding site
Overlay of the two structures reported here shows that
the main zinc binding site in the NRP2 b1 domain is
remote from the VEGF ligand binding site (Fig. 4A),
and is unlikely to directly affect ligand binding. Inter-
estingly, although remote from the VEGF binding
pocket, zinc ion binding site ‘1’ is located at the edge
of the interface between the b1 and b2 domains
(Fig. 4A). All neuropilin structures published so far
[28,30,31] that contain tandem b1b2 domains exhibit
an extensive inter-domain interface, providing fixed
orientation of the two constituting domains. Binding
of a zinc ion in that region may affect the interface
and overall protein conformation and stability.
Overlay of our structure with that of the b1b2 domain
(PDB ID 2QQJ) shows that, in addition to the adjust-
ments of the side-chain positions required for ion
binding, there is a significant effect on the position of
backbone residues and temperature factors in this area
(Fig. 4B). There is a localized backbone displacement
of 1–2 A for atoms of NRP2 residues in the regions
spanning Tyr375–Asn380 and Ala400–Leu403. Binding
of zinc also resulted in reduction of thermal motions
of the corresponding atoms (Fig. 4B).
Zinc ion binding was further investigated using ITC.
Consistent with our crystal structure, the binding curve
of zinc ion titration into the wild-type NRP2 b1
domain is fitted with three binding sites (Fig. 5). Our
ITC experiments identified the highest-affinity binding
site (site ’1’), with a dissociation constant (KD) of
1.1 lM. This affinity is expected for a binding site with
three side chains coordinating the ion, and is within
the range of affinity constants for other physiologically
relevant zinc-binding proteins [32]. The micromolar
affinity of NRP2 for zinc suggests that, rather than
having a structural role, this zinc binding site may
have a regulatory function that is exhibited at times of
fluctuating physiological zinc concentrations. The
other two dissociation constants that were obtained,
Fig. 3. Structure of the VEGF-A165-derived
peptide bound to the NRP2 b1 domain.
(A) The amino acid sequences of the
heparin binding domain of VEGF-A165 and
the related bicyclic peptide EG00086.
Disulfide links are indicated. The
numbering corresponds to the full-length
VEGF-A form. (B) A maximum of eight
C-terminal residues of EG00086 (sticks)
were detected in the electron density
maps of the molecular complex. The
peptide binds to the canonical ligand
binding site flanked by loops L1 and L3.
(C) Detailed view of the interactions
between the peptide and NRP2. Relevant
residues have been labelled, and the
specific hydrogen bonds and charge–
charge interactions are indicated by
dashed lines. The 2 Fo – Fc electron
density map (grey mesh) showed
significant disorder for the peptide region;
in this image, the associated electron
density map is contoured at 0.6 r.
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11.9 and 149.9 lM, indicate much weaker affinity and
may not be of physiological importance. When his-
tidine residues in site ‘1’ were mutated to alanines
(His377Ala and His399Ala), the NRP2 b1 domain was
still able to bind zinc, but the titration curve was con-
sistent with the presence of two binding sites (Fig. 5)
with dissociation constants of 20.7 and 143.5 lM. The
two zinc binding sites identified in the His377Ala/
His399Ala NRP2 b1 variant have measured affinities
comparable to those of the two weaker binding sites
identified in wild-type NRP2 b1. This observation con-
firms that histidine to alanine mutation of residues 377
and 399 results in abolition of zinc binding site ‘1’.
ITC was also used to confirm that the His377Ala/
His399Ala mutations did not affect the ligand binding
potential of the resultant protein (Fig. 6), with
EG00086 association constants of 1.07E5  1.63E4
and 0.96E5  1.68E4 M1 for the wild-type and
mutant protein, respectively.
NRP2 thermal stability is decreased in the
presence of zinc
To further investigate the effect of zinc on NRP2, we
performed a fluorescence-based thermal denaturation
assay, which supported our hypothesis that the zinc
ion affects the stability of the NRP2 b1b2 protein.
Using this rapid, qualitative assessment, we observed
that, in the presence of zinc ions, there is a significant
negative shift in thermal denaturation curves for all
concentrations of Zn2+ used. As an example of the
effect, Fig. 7 presents thermal denaturation curves
showing that the melting temperature (Tm) for the
NRP2 b1b2 protein decreased by 2 °C (Tm for NRP2
b1b2 = 44.5 °C; Tm for NRP2 b1b2-Zn
2+ = 42.5 °C)
in the presence of an equimolar amount of zinc. The
crystal structure of the b1 domain revealed that Zn2+
bound to site ‘1’ bridges the two structural loops that
contain the Zn2+-coordinating residues, thereby
restricting their flexibility, as determined by the local-
ized reduction in temperature factors. However, in the
context of the b1b2 protein, this localized conforma-
tional distortion at the inter-domain interface may
contribute to overall loss of thermodynamic stability.
The Tm decreased even further with an increase in zinc
ion concentration (data not shown), most likely due to
inter-molecular zinc binding, causing aggregation and
faster denaturation. Importantly, not only did the
presence of an equimolar concentration of zinc result
in NRP2 destabilization, the melting temperature of
the histidine to alanine double mutant is itself 1 °C
lower than that of wild-type NRP2 b1b2 (Fig. 7), sug-
gesting that the mutations at site 1 may disrupt the
b1/b2 interface at some level, and decrease the overall
stability of the variant protein. The effect of zinc in
the context of the histidine to alanine double mutant
Fig. 4. Zn2+ ions bind remotely from the peptide ligand binding site on NRP2. (A) Overlay of the two structures reported here (yellow and
orange, EG00086 and Zn ion-bound respectively) with the structure of the NRP2 b1b2 domains (PDB ID 2QQJ) (grey) shows that the main
zinc binding site is located near the interface of domains b1 and b2, remote from the ligand binding region. EG00086 is shown using sticks
representation, and the zinc ion is indicated by a grey sphere. (B) Close-up view of the conformational changes associated with Zn2+
binding. The zinc-bound structure shown in yellow is compared to NRP2 b1b2 domains (PDB ID 2QQJ), shown in grey. In this
representation, the backbone thickness correlates with the values of the temperature factors for the corresponding backbone atoms.
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of NRP2 b1b2 is a consequence of zinc ion binding in
an inter-molecular fashion, leading to protein aggrega-
tion and denaturation.
Heparin provides protection from zinc-induced
protein instability
Thermal shift assays have also shown that heparin
provides protection from zinc-induced thermal denatu-
ration of NRP2 b1b2 (Fig. 7). It has been reported
previously that heparin oligosaccharides bind NRP1
b1b2 and induce protein dimerization [30], and we
used ITC to further examine the effect of heparin on
the NRP2 b1b2 structure. When heparin oligosaccha-
rides (20-mer) were titrated into NRP2 b1b2, the ITC
binding curve was consistent with two binding events
characterized by dissociation constants of 0.33 and
5.81 lM (Fig. 8A). The ITC curve also suggests that,
in the initial stages of titration, both binding sites on
the heparin molecule (higher- and lower-affinity sites)
are occupied by NRP2 b1b2, indicative of a stoichiom-
etry of one molecule of heparin to two molecules of
NRP2; but as the heparin concentration increases
within the sample chamber, the higher-affinity binding
site is preferentially occupied until all of the NRP2
b1b2 molecules are heparin-bound in a 1 : 1 stoi-
chiometry. Even though heparin and NRP2 b1b2 form
a 1 : 1 binding complex, heparin-bound NRP2 b1b2
following ITC titration forms a dimer, as suggested by
the size-exclusion chromatography profile. In addition
to inducing NRP2 b1b2 dimerization, heparin affects
the stability of the NRP2 b1b2 protein, resulting in an
Fig. 5. Mutation of residues His377 and His399 leads to a loss of NRP2 b1 domain affinity for zinc. Isothermal titration of ZnCl2 and site-
directed mutagenesis were used to confirm the role of residues His377 and His399 in ion binding. The panels on the left show the raw data
(top) and the binding isotherm (bottom) for the wild-type protein, while the panels on the right correspond to the double mutant NRP2 b1b2
protein titrated with ZnCl2.
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Fig. 6. ITC confirmed that mutation of His377 and His399 to Ala did not affect the interaction of the NRP2 b1 domain with EG00086. The
panels on the left show the raw data (top) and the binding isotherm (bottom) for the wild-type protein, while the panels on the right
correspond to the double mutant NRP2 b1b2 protein titrated with EG00086.
Fig. 7. Zinc binding destabilizes NRP2
b1b2 protein. The results of thermofluor
assays for the wild-type protein (top) and
the mutant protein (bottom) in the
presence of Zn2+ and/or heparin
demonstrate the protective function of
heparin with respect to the protein
instability introduced by zinc ion binding.
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increase in the Tm of heparin-bound NRP2 b1b2 by
5.5 °C compared to NRP2 b1b2 alone (Tm = 50 °C
and 44.5 °C, respectively) (Fig. 7). To assess the influ-
ence of heparin on zinc-bound NRP2 b1b2
(Tm = 42.5 °C), we incubated a zinc/NRP2 b1b2 mix-
ture in the presence of heparin for 30 min prior to the
thermal shift assay. The presence of heparin effectively
reversed the detrimental effect that zinc has on NRP2
b1b2 stability, with a Tm of 50 °C for heparin-bound
NRP2 b1b2 in the absence and presence of zinc
(Fig. 7).
Based on the putative heparin binding site on NRP1
proposed by Vander Kooi et al. [30], we identified the
corresponding region of the NRP2 b1b2 molecular
surface that carries positive charge and thus may
potentially be involved in heparin binding (Fig. 8B).
Interestingly, the putative heparin binding region and
zinc binding site ‘1’ are close to each other. The prox-
imity of the two binding sites may explain, at least in
part, the protective effect of heparin with respect to
protein destabilization induced by zinc. It is also possi-
ble that zinc and oligosaccharides present in the extra-
cellular matrix, although having opposite effects, are
both involved in regulating the signalling function of
NRP2.
Discussion
We have reported the first crystal structure of a com-
plex between the peptide corresponding to the C-termi-
nus of VEGF-A165 and the b1 domain of NRP2. The
structure suggests that the atomic details of direct
molecular interactions between the b1 protein domain
of NRP2 and the C-terminal ends of VEGF isoforms
Fig. 8. The putative heparin binding region on NRP2 and zinc binding site ‘1’ are close to each other. (A) ITC data for the interaction
between heparin and NRP2 b1b2 protein. The top panel shows raw data while the bottom panel shows the binding isotherm obtained by
integrating peaks from the top panel. The curve is consistent with the occurrence of two binding events followed by NRP2 dimerization. (B)
The NRP2 molecular surface electrostatic potential for the b1b2 domains (PDB ID 2QQJ) is overlaid with the molecular surface for the
a1a2b1b2 ectopic region of NRP2 (PDB ID 2QQK), shown in grey. The zinc ion binding site in the NRP2 structure reported here is indicated
by a grey sphere, and the region of the positive electrostatic surface potential analogous to the NRP1 heparin binding site is outlined using
a dashed line.
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A and C are similar, as seen from comparisons
between the structure reported here (including VEGF-
A165) and that of the structure containing the C-termi-
nus of VEGF-C [27]. The level of structural similarity
is somewhat surprising given that NRP1 and NRP2
have distinct physiological preferences for the growth
factors, with VEGF-A165 being the main NRP1 ligand,
and VEGF-C signalling primarily through NRP2. Pre-
viously, it has been suggested that electrostatic steering
provides the mechanism for ligand selectivity between
neuropilins and various VEGF isoforms [26]. In fact,
comparison of the EG00086-bound NRP2 b1 structure
with that of the NRP1 b1–VEGF-A165-HBD fusion
protein shows two significantly different positions of
VEGF-A165-HBD with respect to the neuropilin b1
domain. The backbone of EG00086 is tilted away from
the NRP2 molecule, indicating an almost 90° differ-
ence in the putative positioning of VEGF-A165-HBD
compared to that suggested by Parker et al. for the
NRP1 structure [26]. The structure reported here sup-
ports the hypothesis that VEGF-A165 does not
approach the NRP2 binding pocket in the same way
as the binding pocket of NRP1 due to differences in
the L1 loop of the binding pocket [26]. However, it is
possible that, in the context of the fusion protein
NRP1 b1–VEGF-A165-HBD and/or under the specific
crystallization conditions, VEGF-A165-HBD was
constrained to adopt the observed orientation. It is
probable that additional elements of the molecular
repertoire, such as glycosylation and other post-trans-
lational modifications (of either NRPs or VEGF mole-
cules), may be important determinants of the ligand
recognition mechanism of neuropilins and their
physiological function in the context of cell-surface
signalling assemblies.
NRP2 is a key molecule in chemotactic migration of
monocyte-derived dendritic cells, and this function is
dependent upon polysialic acid modification of NRP2
[33–35]. Polysialylation is a rare post-translational
modification that has best been described in the con-
text of the neural cell adhesion molecule. NRP1 is not
modified by polysialylation; however, it has been
shown that NRP1 may be modified by chondroitin sul-
fate attachment to Ser612, and that this modification
results in reduced cell migration and invasiveness com-
pared to cells expressing non-glycosylated NRP1
[36,37]. Ser612 is located in the peptide linker region
between the b2 domain and the membrane-proximal c
domain of NRP1. Similarly, mass spectrometry
analysis of polysialylated NRP2 confirmed that
polysialylation modification also occurs in the
equivalent region between the NRP2 b2 and c domains
[38]. NRP2 enhances chemotaxis of dendritic cells
towards the chemokine CCL21 in a polysialylation-
dependent fashion, directing dendritic cells to lym-
phoid organs for activation of naive T cells via antigen
presentation.
Our structural studies additionally revealed a new
feature of the NRP2 b1 domain structure, namely
three Zn2+ binding sites, of which the most biologi-
cally relevant involves coordination of a Zn2+ ion with
residues Tyr375, His377 and His399. The location of
these residues, remote from the main VEGF binding
pocket, suggests that Zn2+ binding is unlikely to have
a strong influence on NRP2–ligand interaction. ITC
experiments have confirmed that mutations of His377
and His399 had no effect on ligand binding. However,
mutation of His377 and His399 markedly decreased
the thermal stability of the NRP2 b1 domain as
revealed by thermal shift assays, an effect that was res-
cued by heparin binding to the NRP2 b1 domain. We
predict that zinc binding to the b1/b2 inter-domain
interface would disrupt NRP2 structure and membrane
organization, and possibly affect ligand recognition.
However, in our experiments, binding of a model
glycan (heparin) to NRP2 supported protein dimeriza-
tion and protected NRP2 from zinc binding-induced
instability.
The physiological role of Zn2+ binding to NRP2 is
unclear, but, interestingly, NRP2 has been strongly
implicated in maturation of dendritic cells, a process
in which zinc homeostasis also plays a crucial role [39–
41]. Although the molecular mechanisms through
which zinc affects maturation of dendritic cells are not
well characterized, it has been shown that expression
of molecules of the major histocompatibility complex
on the plasma membrane correlates with a decrease in
the expression of zinc transporters that move zinc into
the cytosol, reduction of intracellular zinc, and an
increase in the expression of zinc transporters that
transfer ions in the opposite direction across the
plasma membrane [39]. Our structural identification
and in vitro investigation of Zn2+/NRP2 interactions
lay the foundation for further exploration of the
effects of zinc homeostasis on neuropilin functions and
ligand binding.
Experimental procedures
Plasmids
Plasmids expressing recombinant NRP2 domains and
VEGF-A165-HBD have been described previously [42].
Wild-type or mutant pET15b-TEV:nrp2-b1, pET15b-TEV:
nrp2-b1b2 constructs were transformed into Rosetta-gami 2
(DE3)pLysS cells (Novagen, Merck, Darmstadt, Germany),
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while pET14b:VEGF-A165-HBD was transformed into
SHuffle cells (New England Biolabs, Ipswich, MA, USA).
Site-directed mutagenesis
The primers designed to introduce the H377A mutation
were 50-CCTTGTGGTTTTTGCCAGCCCGGTACACCA
TC-30 and 50CTGGATGGTGTACCGGGCTGGCAAAA
ACCAC-30. Those designed to introduce the H399A
mutation were 50-GTCAGCAGTGGAGCGGCGAGCT
TGTTCAGAAC-30 and 50-GGTTCTGAACAAGCTCG
CCGCTCCACTGCTG-30. PCR was performed using Phu-
sion high-fidelity DNA polymerase (New England Biolabs)
according to the manufacturer’s instructions. In each reac-
tion, 10 ng template (pET15b-TEV:nrp2-b1 or pET15b-
TEV:nrp2-b1b2) was added. The PCR product was treated
with DpnI at 37 °C for 1 h to cleave the mother template,
followed by transformation of Escherichia coli DH5a cells
(Invitrogen, Thermo Fisher Scientific, Carlsbad, CA, USA).
The presence of the doubly mutated gene sequence
(His377Ala/His399Ala) was confirmed by DNA sequencing
(Source BioScience, Nottingham, UK).
Expression and purification of recombinant
proteins
To over-express NRP2 b1, NRP2 b1b2 and VEGF-A165-
HBD, 10 mL overnight cultures were transferred into 1 L
of LB medium containing the appropriate antibiotics, and
cells were grown at 37 °C until the attenuance at 600 nm
reached 0.6. All cultures were grown in the presence of 100
ugml1 of ampicillin. In addition, tetracyclin at 12.5
ugml1 and chloramphenicol at 34 ugml1, were used
when growing Rosetta-gami 2 (DE3)pLysS cells. Protein
expression was induced by addition of isopropyl-b-D-thio-
galactopyranoside at a final concentration of 0.5 mM, and
the cells were left overnight at 30 °C on an orbital shaker.
Cells were harvested by centrifugation at 3993 g at 4 °C
for 15 min, and washed once for 15 min with ice-cold
buffer A containing 50 mM Tris/HCl, pH 7.9, 300 mM
NaCl and 30 mM imidazole. Cells were frozen and stored
at 20 °C until used for protein purification.
Cells over-expressing recombinant NRP2 b1 or b1b2
domains were resuspended in buffer A supplemented with
EDTA-free protease inhibitor (one tablet per 50 mL buffer,
Roche) and lysed by sonication. The cell lysate was clari-
fied by centrifugation at 39 100 g at 4 °C for 30 min. Sol-
uble cell lysate was passed over a pre-equilibrated nickel
ion-chelating affinity column (HisTrap column, GE Health-
care, Little Chalfont, UK). Tagged proteins were eluted at
a flow rate of 1 mLmin1 using a linear gradient of
buffer B (50 mM Tris/HCl, pH 7.9, 300 mM NaCl, 600 mM
imidazole). Recombinant tobacco etch virus protease was
mixed with eluted His-tagged proteins, followed by dialysis
against 4 L of 50 mM Tris/HCl, pH 8.0, 300 mM NaCl,
20 mM imidazole, 0.3 mM L-cysteine and 3 mM L-cystine at
4 °C overnight. Following dialysis, protein samples were
incubated with pre-equilibrated Ni-NTA agarose (Qiagen,
Hilden, Germany) for 30 min at 4 °C. Ni-NTA agarose
beads were pelleted by centrifugation at 3700 g at 4 °C for
10 min. The supernatant was collected and loaded onto a
HiTrap Heparin HP column (GE Healthcare) pre-equili-
brated with 50 mM Tris/HCl, pH 7.9, 100 mM NaCl. Target
protein was eluted at 1 mLmin1 using a linear gradient of
high-salt buffer comprising 50 mM Tris/HCl, pH 7.9, 2 M
NaCl. Eluted recombinant neuropilin protein fractions were
pooled, subjected to buffer exchange into 20 mM Tris/HCl,
pH 7.9, 50 mM NaCl, and stored at 4 °C.
Cells over-expressing recombinant VEGF-A165-HBD
were lysed, and His-tagged proteins were purified using a
nickel-chelating affinity column as described above. Throm-
bin was mixed with His-tagged VEGF-A165-HBD, followed
by dialysis against 4 L of 20 mM Tris pH 8.4, 150 mM
NaCl, 2.5 mM CaCl2, at room temperature overnight.
Tagged and untagged proteins were separated by incuba-
tion with Ni-NTA agarose as described above. Untagged
proteins were further purified using a HiTrap Heparin (HP)
column pre-equilibrated with 50 mM Tris/HCl, pH 7.9,
100 mM NaCl (GE Healthcare). Target protein was eluted
at the flow rate of 1 mLmin1 using a linear gradient of
high-salt buffer containing 50 mM Tris/HCl, pH 7.9, 2 M
NaCl. Fractions containing VEGF-A165-HBD were pooled,
concentrated and loaded onto a pre-equilibrated Superdex-
75 size-exclusion column (GE Healthcare). VEGF-A165-
HBD was eluted at 1 mLmin1 using buffer containing
50 mM Tris/HCl, pH 7.5, 100 mM NaCl. Samples were
pooled, sparated into aliquots, and stored at 20 °C.
Peptide synthesis
Synthesis of the bicyclic peptide, EG00086, containing the
C-terminal 28 amino acid residues of VEGF-A165 encoded
by exons 7 and 8 (equivalent to VEGF-A138–165), was
performed as previously described [29].
X-ray crystallography
Purified NRP2 b1 domain at 10 mgmL1 was crystallized
in the presence of zinc sulfate. Protein was mixed with
mother liquor (25% PEG 550 MME, 0.1 M MES, pH 6.5,
0.01 M ZnSO4) at a 1 : 1 ratio, and crystals were grown at
16 °C by the vapour diffusion method. X-ray diffraction
data were obtained at the European Synchrotron Radiation
Facility (Grenoble, France) at 1.8 A resolution, and
belonged to space group C2221.
Formation of a complex of the NRP2 b1 domain and
peptide EG00086 was confirmed by ITC, after which the
sample was collected from the titration cell. The sample
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contained a 1 : 2 molar ratio of protein to ligand in 20 mM
Tris/HCl, pH 7.9, 50 mM NaCl, and NRP2 b1 at a concen-
tration of 10 mgmL1. The protein complex was mixed
with mother liquor (10% PEG 20 000, 0.1 M bicine pH 9.0,
2% dioxane) at a 1 : 1 ratio, and crystals were grown at
16 °C by the vapour diffusion method. X-ray diffraction
data were collected at the Diamond Light Source (Didcot,
UK) at 2 A resolution, and belonged to space group C2221
with cell dimensions of a = 110.25 A, b = 139.52 A,
c = 106.04 A, a = 90.00°, b = 90.00° and c = 90.00°.
Data were merged and indexed using iMosflm [43,44].
The structure was solved by molecular replacement using
PHASER [45] with the apo NRP2 b1 domain (PDB ID
2QQJ) [28]. Iterative rounds of refinement were performed
using COOT [46] and REFMAC5 [47,48]. CC½ values were
obtained from unmerged data using AIMLESS [49].
Isothermal titration calorimetry
Wild-type and mutants of the NRP2 b1 or b1b2 domains
were dialysed in 20 mM Tris/HCl, pH 7.9, 50 mM NaCl at
4 °C overnight. Protein was loaded into the cell at 40–
200 lM concentration, while ZnCl2 was loaded in the syringe
at 1.5–5 mM. Zinc titration was performed at 21 °C using 98
injections in a MicroCal iTC200 system (GE Healthcare).
EG00086 titration was performed at 15 °C with 19 injections
using 40.3 lM protein sample in the cell and 600 lM
EG00086 peptide in the syringe. VEGF-A165-HBD titration
was performed at 10 °C with 19 injections, with 80 lM pro-
tein sample in the cell and 2.1 mM VEGF-A165-HBD in the
syringe. Titration of heparin oligosaccharides was performed
at 21 °C with 39 injections of 300 lM heparin oligosaccha-
rides in the syringe and 36 lM purified NRP2 b1b2 domain
in the cell. Data were evaluated using ORIGIN ver-
sion 7.0 software (OriginLab, Northampton, MA, USA)
with the ITC plug-in provided by the manufacturer.
Thermofluor assay
The wild-type and mutated NRP2 b1b2 domains (45 lM)
were mixed with 0, 10, 25, 45, 80, 150, 200 or 300 lM ZnCl2
in 20 mM Tris/HCl, pH 7.9, 50 mM NaCl, at room tempera-
ture for 30 min before mixing with SYPRO Orange protein
gel stain (final dilution 1 : 1250; Life Technologies, Carls-
bad, CA, USA). In the experiments including heparin, 45 lM
protein samples were mixed with 45 lM ZnCl2 at room tem-
perature for 30 min before addition of 45 lM heparin
oligosaccharide dp20 (molecular mass 5750 Da; Iduron,
Alderley Edge, UK). The samples were left at 4 °C for
30 min, and then mixed with the dye. The thermofluor assay
was performed at 10–95 °C with a 0.5 °C step increment over
75 min using a MyiQ RT-PCR instrument (Bio-Rad,
Hercules, CA, USA). Experiments were performed in tripli-
cate. Data were evaluated using IQ5 software (Bio-Rad).
Accession numbers
The the EG00086 and Zn2+-bound structures have been
submitted to the Protein Data Bank under accession num-
bers 5DN2 and 5DQ0, respectively.
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